• BMAL1 Phase Separation Orchestrates Circadian Transcriptiona

  2026-07-14

  Gao et al. demonstrate that BMAL1, a core circadian clock factor, regulates rhythmic gene expression through phase separation, forming dynamic nuclear condensates. Their work reveals a direct link between the phosphorylation state of BMAL1’s intrinsically disordered region and the spatiotemporal control of transcription, offering refined strategies for mechanistic studies of protein phosphorylation.

• Testosterone Bounce as a Prognostic Biomarker in Degarelix-T

  2026-07-14

  This study provides the first in-depth assessment of testosterone bounce—a temporary rise in serum testosterone above 20 ng/dL—as a biomarker predicting improved overall and cancer-specific survival in prostate cancer patients treated with the GnRH antagonist degarelix. The findings suggest that monitoring testosterone kinetics could refine prognostic stratification beyond traditional PSA-based approaches, potentially influencing future clinical decision-making.

• Olaparib (AZD2281): Mechanisms Driving Translational Oncolog

  2026-07-13

  Explore how Olaparib (AZD2281) exemplifies the convergence of mechanistic insight and strategic innovation in translational cancer research. This article blends latest findings in PAR-dependent biomolecular condensates with actionable guidance for researchers optimizing DNA damage response assays, tumor radiosensitization, and BRCA-associated cancer models—while contextualizing APExBIO’s product in the competitive landscape.

• AZD1390: ATM Kinase Inhibition Transforms Radiosensitization

  2026-07-13

  Explore how AZD1390, a potent ATM kinase inhibitor, redefines radiosensitization in cancer research. This article uniquely links DNA repair innovations to practical assay design, advancing beyond current guides.

• Complete Nicotine Biosynthesis Pathway: Mechanistic Insights

  2026-07-12

  The study by Chang et al. delineates the complete biosynthetic pathway of nicotine in tobacco, revealing the roles of glycosylation, a five-component vacuolar metabolon, and a MATE transporter in stereoselective ring coupling and transport. These findings enable precise molecular engineering strategies for nicotine production and pest resistance in heterologous plants, with broad implications for alkaloid biosynthesis research.

• Hyperthermia Sensitizes BRCA2-Proficient Ovarian Cancer to P

  2026-07-10

  Mei et al. demonstrate that hyperthermia-induced reduction of BRCA2 protein sensitizes otherwise PARP inhibitor-resistant, BRCA2-proficient ovarian carcinoma cells to Niraparib. This work suggests a clinically relevant combinatorial strategy for overcoming intrinsic resistance to DNA damage repair inhibition in ovarian cancer.

• Intranasal Sumatriptan as First-Line Therapy in Pediatric Mi

  2026-07-09

  This study demonstrates that intranasal sumatriptan, a selective 5-HT1 receptor agonist, can serve as an effective and feasible first-line abortive treatment for pediatric migraine in emergency departments. Its use is associated with significant pain reduction and reduced resource utilization, signaling a potential shift in acute pediatric migraine care.

• ATM Inhibition and Fenofibrate Synergy in Ovarian Cancer Cel

  2026-07-09

  This study demonstrates that combining ATM kinase inhibition with the metabolic drug fenofibrate induces synergistic senescence in high grade serous ovarian cancer (HGSOC) cells. The findings uncover metabolic vulnerabilities in HR-proficient HGSOC and suggest new combinatorial strategies for overcoming resistance to current DNA repair-targeted therapies.

• Exosomal HMGB1 Drives Glomerular Endothelial Injury in Lupus

  2026-07-08

  The reference study identifies podocyte-derived exosomes carrying HMGB1 as key mediators of glomerular endothelial cell injury in lupus nephritis by upregulating TRIM27. This mechanistic insight suggests that targeting exosome release or HMGB1 cargo may offer new therapeutic and experimental opportunities for dissecting endothelial dysfunction in LN.

• Shufeng Xingbi Therapy Modulates Immune Balance in Allergic

  2026-07-08

  The referenced study demonstrates that Shufeng Xingbi Therapy (SFXBT) effectively alleviates allergic rhinitis symptoms in rats by restoring Th1/Th2 immune balance and remodeling the intestinal microbiome. These findings highlight a mechanistic link between mucosal immunity, microbiota, and anti-inflammatory interventions, informing future research into immunomodulatory therapies for allergic diseases.

• Medroxyprogesterone Acetate: Precision in Hormone Research W

  2026-07-07

  Medroxyprogesterone acetate (MPA) empowers researchers to model steroid hormone signaling with high reproducibility, spanning renal, reproductive, and neurobiological systems. Discover how APExBIO’s MPA enhances protocol robustness, enables advanced assay design, and bridges translational gaps in hormone-driven disease research.

• Phosphotungstic Acid Negative Stain Solution: Precision in V

  2026-07-07

  Unlock ultra-precise electron microscopy with 2% Phosphotungstic Acid Negative Stain Solution for visualizing macromolecules, viruses, and conserved glycan targets. This guide bridges breakthrough glycan-targeting virology with applied EM workflows, offering actionable troubleshooting and protocol enhancements for advanced imaging.

• 17-AAG (Tanespimycin): Workflow Optimization for HSP90 Inhib

  2026-07-06

  17-AAG (Tanespimycin) enables precise, reproducible HSP90 chaperone inhibition for advanced cancer research and mechanistic studies. This guide translates the latest cross-domain insights, including selective protein secretion, into actionable protocols and troubleshooting strategies for maximizing experimental clarity.

• BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Parame

  2026-07-06

  BFH772 is a highly selective VEGFR2 inhibitor designed for research requiring precise disruption of VEGFR2-mediated angiogenesis, especially in tumor model systems. It should not be used in workflows demanding water solubility or broad-spectrum kinase inhibition due to its solubility profile and receptor selectivity.

• Optimized Sulfonamides Target TB with Reduced CYP 2C9 Inhibi

  2026-07-05

  Chen et al. systematically optimized sulfonamide derivatives of sulfaphenazole to combat Mycobacterium tuberculosis while reducing cytochrome P450 2C9 inhibition. Their approach highlights new therapeutic avenues for tuberculosis with improved safety regarding drug–drug interactions.

11527 records 1/769 page Next 12345 下5页 Last page